Bupivacaine Injections

Bupivacaine is a long‐acting amide local anesthetic used for surgical and pain blocks (infiltration, nerve blocks, epidural, etc.). It is chemically related to lidocaine/mepivacaine but is more lipid‐soluble and protein-bound, giving it a slower onset and much longer duration of anesthesia. Brand names include Marcaine and Sensorcaine (bupivacaine HCl) for injections, and Exparel for the liposomal (extended-release) formulation. Bupivacaine works by blocking voltage-gated sodium channels in nerve membranes, preventing depolarization and thus nerve impulse conduction. In clinical order, sensation lost is pain → temperature → touch → motor function.

Available Strengths and Formulations

Bupivacaine injections come in several concentrations (all as mg per mL):

• 0.25% (2.5 mg/mL): Provides mild anesthesia with minimal motor block. Used for minor infiltration or prolonged procedures not requiring deep muscle relaxation. (Available as Marcaine/Sensorcaine 0.25% in 10 mL or 30 mL single-dose vials and 50 mL multi-dose vials.
• 0.5% (5 mg/mL): The most common standard strength. Used for many peripheral nerve blocks, epidural labor analgesia, dental procedures, etc. (Available in 10 mL, 30 mL single-dose and 50 mL multi-dose vials.
• 0.75% (7.5 mg/mL): A higher concentration for deeper anesthesia (e.g. surgical blocks requiring complete motor block, retrobulbar eye blocks, some epidurals). Not recommended for obstetrical epidurals due to reports of cardiotoxicity. (Sold in 10 mL and 30 mL vials; e.g. Marcaine 0.75%.)
• With epinephrine (1:200,000): Bupivacaine 0.25% and 0.5% are also available combined with epinephrine to constrict blood vessels, slow absorption, and prolong duration (e.g. Marcaine with epi 0.5% in 1:200,000). Epinephrine-containing solutions carry additional warnings (see below).
• Other formulations: A 0.75% (7.5 mg/mL) heavy solution with 8.25% dextrose is sold as LIDOCAINE Marcaine™ Spinal for intrathecal (spinal) anesthesia (hyperbaric block). The liposomal form, Exparel®, contains 1.3% bupivacaine (13.3 mg/mL) in a slow-release formulation for post-surgical infiltration (multi-dose vial or syringe). (Exparel is FDA-approved for wound infiltration, not for nerve blocks.)

Typical packaging sizes are 10 mL or 30 mL single-dose vials and 50 mL multi-dose vials, depending on manufacturer and strength. Each vial is colorless solution. Marcaine and Sensorcaine products are chemically identical; the “MPF” designation indicates Methyl Paraben Free (sterile preservative-free) single-dose formats.

Packaging and Brands

Brands: The most common commercial names are Marcaine™ (by Pfizer) and Sensorcaine™ (by AstraZeneca/Fresenius Kabi). Both supply bupivacaine HCl injection in the strengths above, with and without epinephrine. Exparel® (Pacira) is a liposomal bupivacaine (1.3%) for infiltration. Bupivacaine 0.75% with dextrose is marketed as Marcain Spinal for intrathecal use (Pacira also sells non-liposomal Marcaine® Spinal heavy).

Pack sizes: Typical vials are 10 mL or 30 mL single-dose vials or 50 mL multi-dose vials (for example, Marcaine 0.5% comes in 10 mL, 30 mL and 50 mL vials). The Multi-dose vials contain a preservative (methylparaben) whereas “MPF” single-dose vials do not. Each mL of solution contains only bupivacaine (and possibly epinephrine); carriers include normal saline and minimal sodium citrate (to adjust pH). Unused opened vials (without preservative) should be discarded after 24 hours.

All injection vials should be stored at controlled room temperature (no refrigeration needed) and protected from light. Check the expiration date—discard any solution that has changed color or clarity. Do not reuse syringes or share vials between patients (risk of contamination and dosing errors).

Mechanism of Action

Bupivacaine works by reversibly blocking voltage-gated sodium (Na⁺) channels on nerve fibers. Normally, these channels allow sodium influx to generate action potentials (nerve impulses). When bupivacaine binds inside the channel (especially when the channel is open), it prevents Na⁺ from entering, so the nerve cannot depolarize. In effect, the nerve impulse is halted and pain signals cannot travel to the brain, producing a localized numbness.

• Because of its chemical structure, bupivacaine is an amide-type local anesthetic (like lidocaine), which generally has lower allergy risk than ester-type anesthetics.
• Bupivacaine is highly lipid-soluble (high potency) and has a relatively high pKa, so onset is somewhat slower than lidocaine but it produces a long duration of anesthesia (often several hours).
• In the heart and cardiovascular system, bupivacaine also blocks sodium (and other) channels. Due to its slow unbinding from the channel, it prolongs refractory periods in cardiac muscle, which can depress cardiac conduction and cause dangerous arrhythmias if the drug reaches high blood levels. This cardiac effect underlies why bupivacaine has a high risk of cardiotoxicity compared to other local anesthetics.

Administration Routes and Uses

Bupivacaine is administered by a healthcare professional, typically by injection in or around nerves or the spine. Common injection routes include:

• Peripheral nerve block: Injected near a nerve or nerve plexus (e.g. brachial plexus block for arm surgery, dental nerve blocks, intercostal nerve block).
• Local infiltration: Injected into surgical wounds or tissues for postoperative analgesia (e.g. after tooth extraction, knee surgery).
• Epidural anesthesia/analgesia: Injected into the epidural space of the spine (e.g. during labor or cesarean delivery, or for pain control after abdominal surgery).
• Spinal (subarachnoid) anesthesia: Injected into the cerebrospinal fluid (CSF) in the spinal canal for procedures like lower-limb orthopedic surgery or cesarean section.
• Caudal block: A type of epidural given through the lower spine (sacral hiatus) mainly used for pediatric lower-body procedures.

Each route and dose is chosen based on the procedure and desired duration of numbing. Bupivacaine is often formulated at 0.25%, 0.5%, or 0.75% concentrations, and can be combined with a small amount of epinephrine (a vasoconstrictor) to prolong its effect and reduce systemic absorption. Whichever route is used, injections must be performed under strict sterile conditions and with monitoring, since bupivacaine’s potency and slow clearance make toxicity a serious concern.

Effects and Duration

After injection, bupivacaine numbs the targeted area by preventing sensory (and eventually motor) nerve signals. Patients feel numb rather than sedated; consciousness is maintained. Bupivacaine has a slow to intermediate onset and a long duration of action relative to shorter-acting agents like lidocaine. For example, analgesia can last from several hours to up to 8–12 hours depending on dose, concentration, and use of epinephrine. Because of this long action, bupivacaine is often chosen for procedures or postoperative pain control where extended anesthesia is desired.

Adverse Effects and Toxicity

When used properly at recommended doses, bupivacaine provides safe local anesthesia. However, systemic toxicity can occur if too much drug enters the bloodstream or is injected into highly vascular areas. Warning signs of systemic toxicity (sometimes called LAST – Local Anesthetic Systemic Toxicity) include neurologic and cardiac symptoms. Key points:

• Neurologic effects: Early CNS symptoms can include numbness of the tongue or mouth, tinnitus (ringing in the ears), dizziness, blurred vision, and tremors. At higher blood levels, generalized central nervous system depression can occur, including convulsions (seizures), loss of consciousness, and coma.
• Cardiovascular effects: Bupivacaine is notorious for cardiotoxicity. It can cause bradycardia, severe hypotension, conduction blocks, and fatal ventricular arrhythmias (e.g. ventricular tachycardia or fibrillation) due to its strong blockade of cardiac Na⁺ channels. In fact, among local anesthetics, bupivacaine has one of the highest risks of causing life-threatening cardiac complications if overdose occurs.
• Other effects: Allergic reactions to bupivacaine are rare (most true allergies occur with ester-type anesthetics). Other side effects can include nausea, vomiting, shivering, headache, or hypotension from sympathetic block. Methemoglobinemia (abnormal hemoglobin) is exceedingly rare with bupivacaine but has been reported.

The risk of toxicity depends on dose and site of injection. Intravenous injection (accidental intravascular injection) or injections in highly vascular areas (e.g. intercostal blocks) carry the greatest absorption risk. To minimize risk, practitioners aspirate before injecting and give fractional doses, while continuously monitoring the patient.

Management of Overdose (Local Anesthetic Systemic Toxicity)

If signs of bupivacaine toxicity appear (e.g. sudden seizure, severe arrhythmia), immediate treatment is critical. Guidelines recommend airway support, seizure control (benzodiazepines, if needed), and cardiovascular support. A key therapy for lipophilic anaesthetic toxicity is intravenous lipid emulsion (often 20% lipid infusion). Experimental and clinical data show that early administration of lipid emulsion can “rescue” patients from severe bupivacaine-induced cardiovascular collapse. Facilities using long-acting anesthetics should have lipid emulsion readily available for LAST emergencies.

Contraindications and Precautions

Bupivacaine injection should not be used in patients with known hypersensitivity to it or other amide anesthetics. It is also contraindicated in some specific scenarios: for example, it should not be used in intravenous regional (Bier) blocks and certain obstetric blocks (paracervical blocks or high-concentration obstetric epidurals). Caution is needed in patients with severe liver disease, heart block, low blood pressure, or other conditions that reduce cardiac function, since impaired clearance or added cardiac effects increase risk. Pregnant women, children, and elderly patients require dose adjustments and monitoring.

In all cases, bupivacaine injections must be administered by qualified healthcare professionals with proper monitoring (EKG, blood pressure, oxygen). The dose is carefully calculated (typically not exceeding ~2–3 mg/kg total) to avoid toxicity. Patients are informed not to move the numb area until normal sensation returns, to avoid injury during anesthesia.

Summary

In summary, bupivacaine injection is a powerful long-acting local anesthetic used to produce numbness for surgeries, labor, and pain relief. It works by blocking nerve impulses and is given for epidural, spinal, and peripheral nerve blocks. Its benefits include prolonged pain control, but it carries a higher risk of serious cardiac and CNS toxicity than shorter-acting anesthetics. When used by trained clinicians in controlled doses, bupivacaine is an effective and commonly used local anesthetic. Patients receive this medication under medical supervision, and any signs of toxicity (nervousness, dizziness, metallic taste, seizures, arrhythmia) are treated immediately – often with lipid emulsion therapy and advanced cardiac life support as needed.